TY - JOUR
T1 - Mortality reduction with β-blockers in ischemic cardiomyopathy patients undergoing coronary artery bypass grafting
AU - Lin, Terence
AU - Hasaniya, Nahidh W.
AU - Krider, Susan
AU - Razzouk, Anees
AU - Wang, Nan
AU - Chiong, Jun R.
N1 - Jun R. Chiong, MD, MPH, Loma Linda University Medical Center, 11234 Anderson Street #4404, Loma Linda, CA 92354E‐mail: [email protected] Coronary artery bypass grafting (CABG) in patients with systolic heart failure (HF) carries high morbidity and mortality rates. Reducing perioperative mortality with β‐blockers (BBs) may help improve outcomes.
PY - 2010/7
Y1 - 2010/7
N2 - Coronary artery bypass grafting (CABG) in patients with systolic heart failure (HF) carries high morbidity and mortality rates. Reducing perioperative mortality with β-blockers (BBs) may help improve outcomes. Analysis of 4903 patients who underwent isolated CABG surgery was performed. In-hospital mortality of systolic HF patients who received BBs was 2.03%; systolic HF patients who did not receive BBs had a mortality of 5.20%. Thirty-day mortality was 2.98% in the patients with systolic HF who received BBs and 6.16% in the patients who did not. β-Blockade did not affect the mortality in patients with preserved systolic function. Cardiogenic shock was a predictor of increased mortality in patients with systolic HF, while BBs reduced mortality. BBs are associated with decreased in-hospital and 30-day mortality in patients with systolic HF. BB therapy should be considered in patients with systolic HF who are undergoing CABG.
AB - Coronary artery bypass grafting (CABG) in patients with systolic heart failure (HF) carries high morbidity and mortality rates. Reducing perioperative mortality with β-blockers (BBs) may help improve outcomes. Analysis of 4903 patients who underwent isolated CABG surgery was performed. In-hospital mortality of systolic HF patients who received BBs was 2.03%; systolic HF patients who did not receive BBs had a mortality of 5.20%. Thirty-day mortality was 2.98% in the patients with systolic HF who received BBs and 6.16% in the patients who did not. β-Blockade did not affect the mortality in patients with preserved systolic function. Cardiogenic shock was a predictor of increased mortality in patients with systolic HF, while BBs reduced mortality. BBs are associated with decreased in-hospital and 30-day mortality in patients with systolic HF. BB therapy should be considered in patients with systolic HF who are undergoing CABG.
UR - http://www.scopus.com/inward/record.url?scp=77955161501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955161501&partnerID=8YFLogxK
U2 - 10.1111/j.1751-7133.2010.00146.x
DO - 10.1111/j.1751-7133.2010.00146.x
M3 - Article
C2 - 20662870
SN - 1527-5299
VL - 16
SP - 170
EP - 174
JO - Congestive Heart Failure
JF - Congestive Heart Failure
IS - 4
ER -